외국의 약물유전정보

Trametinib

미국 FDA   원본 보기 | 번역본 보기

5 WARNINGS AND PRECAUTIONS
5.1 New Primary Malignancies
 - Non-Cutaneous Malignancies
Based on its mechanism of action, dabrafenib may promote growth and development of malignancies with activation of RAS through mutation or other mechanisms.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutationpositive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibition of BRAF V600 mutationpositive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation positive tumor xenografts.

(2018.4.30 업데이트)